(PDF) P2.13-15 Short-Term Responders of NSCLC to EGFR-TKIs

P2.13-15 Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1410

Full Text

Open PDF

Abstract

Available in full text

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.13-23 TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC

Journal of Thoracic Oncology

English

P3.13-14 Identification of Novel Mutations by High-Throughout Sequencing in T790M Wildtype/cMET Unamplified NSCLC With Acquired Resistance to EGFR TKIs

Journal of Thoracic Oncology

English

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

English

P2.13-29 IL-22 Confers Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification

Journal of Thoracic Oncology

English

P1.13-27 a Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC With EGFR Mutations

Journal of Thoracic Oncology

English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy

English

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

Journal of Thoracic Oncology

English

Activation of the BMP-BMPR Pathway Conferred Resistance to EGFR-TKIs in Lung Squamous Cell Carcinoma Patients With EGFR Mutations

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2015

English

P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance

Journal of Thoracic Oncology

English

Amanote Research

P2.13-15 Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1410

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

P1.13-23 TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC

P3.13-14 Identification of Novel Mutations by High-Throughout Sequencing in T790M Wildtype/cMET Unamplified NSCLC With Acquired Resistance to EGFR TKIs

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

P2.13-29 IL-22 Confers Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification

P1.13-27 a Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC With EGFR Mutations

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

Activation of the BMP-BMPR Pathway Conferred Resistance to EGFR-TKIs in Lung Squamous Cell Carcinoma Patients With EGFR Mutations

P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance